Adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases

A combination as claimed in any one of the preceding claims wherein the anticholinergic agent is an ipratropium or an oxitropium salt or solvate thereof.

A combination as claimed in any preceding claim for use as a medicament.

A pharmaceutical composition comprising a selective adenosine A2a receptor agonist, an anticholinergic agent and a pharmaceutically acceptable excipient, diluent or carrier, for administration by the inhaled route in the treatment of an obstructive airways or other inflammatory disease, with the proviso that the anticholinergic agent is not a tiotropium salt.

The use of a selective adenosine A2a receptor agonist or an anticholinergic agent in the manufacture of a medicament for simultaneous, sequential or separate administration of both agents by the inhaled route in the treatment of an obstructive airways or other inflammatory disease, with the proviso that the anticholinergic agent is not a tiotropium salt.

A method of treating of an obstructive airways or other inflammatory disease comprising administering simultaneously, sequentially or separately, by the inhaled route, to a mammal in need of such treatment, an effective amount of a selective adenosine A2a receptor agonist and an anticholinergic agent, with the proviso that the anticholinergic agent is not a tiotropium salt.

An inhalation device for simultaneous, sequential or separate administration of a selective adenosine A2a receptor agonist and an anticholinergic agent in the treatment of an obstructive airways or other inflammatory disease, with the proviso that the anticholinergic agent is not a tiotropium salt.